Andere Kunden interessierten sich auch für
![Chronic hepatitis B: Non-invasive markers predictive of fibrosis]( "Chronic hepatitis B: Non-invasive markers predictive of fibrosis")
Chronic hepatitis B: Non-invasive markers predictive of fibrosis40,99 €![Hepatic fibrosis in non-obese diabetics: myth or reality?]( "Hepatic fibrosis in non-obese diabetics: myth or reality?")
Hepatic fibrosis in non-obese diabetics: myth or reality?29,99 €![Biomarcadores séricos de fibrose e hepatite viral B]( "Biomarcadores séricos de fibrose e hepatite viral B")
Biomarcadores séricos de fibrose e hepatite viral B28,99 €![Evaluation of the combination of ultrasound and elastometry]( "Evaluation of the combination of ultrasound and elastometry")
Evaluation of the combination of ultrasound and elastometry47,99 €![AUTOANTIBODIES IN CHRONIC VIRAL HEPATITIS C]( "AUTOANTIBODIES IN CHRONIC VIRAL HEPATITIS C")
AUTOANTIBODIES IN CHRONIC VIRAL HEPATITIS C29,99 €![Probiotics and hepatoprotectors in the treatment of viral hepatitis A and B]( "Probiotics and hepatoprotectors in the treatment of viral hepatitis A and B")
Probiotics and hepatoprotectors in the treatment of viral hepatitis A and B44,99 €![Viral hepatitis E, clinical, diagnostic and therapeutic aspects]( "Viral hepatitis E, clinical, diagnostic and therapeutic aspects")
Viral hepatitis E, clinical, diagnostic and therapeutic aspects29,99 €
The eLIFT and FIB-4 scores offered the best diagnostic performance, with high sensitivity and specificity for detecting advanced fibrosis and cirrhosis. eLIFT showed a remarkable ability to predict advanced stages of fibrosis thanks to the integration of several parameters. APRI and King Score showed good results, but with lower specificity for advanced stages. These non-invasive serum biomarkers, in particular eLIFT and FIB-4, are proving to be reliable alternatives to invasive methods, enabling faster, more accessible and less costly diagnosis, particularly in resource-limited settings.